Strategic infection prevention after genetically modified hematopoietic stem cell therapies : recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee
Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved..
There is lack of guidance for immune monitoring and infection prevention after administration of ex vivo genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs. Disease-specific and GMHSCT-specific considerations should guide decision making for each therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cytotherapy - (2024) vom: 20. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
John, Tami D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Genetically modified hematopoietic stem cell therapies |
|---|
| Anmerkungen: |
Date Revised 18.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jcyt.2024.02.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369730631 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369730631 | ||
| 003 | DE-627 | ||
| 005 | 20240318234713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcyt.2024.02.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1335.xml |
| 035 | |a (DE-627)NLM369730631 | ||
| 035 | |a (NLM)38483362 | ||
| 035 | |a (PII)S1465-3249(24)00052-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a John, Tami D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Strategic infection prevention after genetically modified hematopoietic stem cell therapies |b recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a There is lack of guidance for immune monitoring and infection prevention after administration of ex vivo genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs. Disease-specific and GMHSCT-specific considerations should guide decision making for each therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a genetically modified hematopoietic stem cell therapies | |
| 650 | 4 | |a immune reconstitution | |
| 650 | 4 | |a prophylaxis | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Maron, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Abraham, Allistair |e verfasserin |4 aut | |
| 700 | 1 | |a Bertaina, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Bhoopalan, Senthil Velan |e verfasserin |4 aut | |
| 700 | 1 | |a Bidgoli, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Bonfim, Carmem |e verfasserin |4 aut | |
| 700 | 1 | |a Coleman, Zane |e verfasserin |4 aut | |
| 700 | 1 | |a DeZern, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Louis, Chrystal |e verfasserin |4 aut | |
| 700 | 1 | |a Oved, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Pavel-Dinu, Mara |e verfasserin |4 aut | |
| 700 | 1 | |a Purtill, Duncan |e verfasserin |4 aut | |
| 700 | 1 | |a Ruggeri, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Russell, Athena |e verfasserin |4 aut | |
| 700 | 1 | |a Wynn, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Boelens, Jaap Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Prockop, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Akshay |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytotherapy |d 1999 |g (2024) vom: 20. Feb. |w (DE-627)NLM118333852 |x 1477-2566 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcyt.2024.02.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 02 | ||